Major Announcement: FDA Clears Oragenics, Inc. (NYSE: OGEN)'s ONP-002 for Next Phase

Immediately Add Oragenics, Inc. (NYSE American: OGEN) to Your Watchlist for This Morning!

Market Crux Exclusive: Immediately Add Oragenics, Inc. (NYSE American: OGEN) to Your Watchlist for This Morning! Oragenics, Inc. (NYSE American: OGEN) Comes Stacked with Several Potential Catalysts Including:  Technical Indicators: Triggering 16 Bullish Signals On TradingView’s Technical Analysis Tool For The 5-Minute Time Frame As Of August 7, 2024, Indicating Strong Positive Sentiment! Low Float And Higher Growth Potential: Less Than 5.1M Shares In Float And A Market Cap Of Less Than $6M, Leading To Potential Price Swings And Higher Growth Compared To Larger Companies! Innovative Biotechnology: Leading In Pharmaceutical Medication Delivery Via Nasal Systems, Focusing On Neurological Conditions And Infectious Diseases! Breakthrough Formulation: Enhanced ONP-002 Formulation For Concussion Treatment Showcasing Oragenics' Innovative Capabilities And Improved Efficacy! Addressing Major Medical Needs: ONP-002 Has The Potential To Significantly Impact Outcomes For The 69 Mln Concussions Reported Annually Worldwide, Reducing Long-Term Disabilities! Promising Phase II Study: Upcoming Phase II Study To Evaluate The Safety And Effectiveness Of ONP-002, Paving The Way For Potential Breakthroughs In Concussion Treatment! Automated Intranasal Device: Development Of An Automated Device For Effective Delivery To Concussed Patients, Addressing Critical Early-Phase Treatment Needs! Do Not Miss Out on Oragenics, Inc. (NYSE American: OGEN)! Major Announcement: FDA Clears Oragenics, Inc. (NYSE: OGEN)'s  ONP-002 for Next Phase! August 8, 2024 Dear Reader, Don’t miss out on Oragenics, Inc. (NYSE: OGEN) as its looking green early on the heels of breaking news! Oragenics, Inc. (NYSE: OGEN) just announced that ONP-002, its lead candidate for treating concussions, has passed FDA-required cardiotoxicity testing. This nasal delivery dr-ug has a strong safety margin based on hERG study results. President Michael Redmond noted, “With ONP-002’s proven safety, we are set to move forward with Phase II trials, with safety as our top priority.” With 69 million concussions reported globally each year, ONP-002 is poised for significant market impact. Concussions, typically caused by falls, accidents, and sports, lead to high healthcare costs and long-term neurological conditions. Get the full story here. But you need to hurry because there’s less than 5.1M shares available in the float and it's currently trending above its 5-Day moving average of $.9545 and eying its 20-Day moving average of $1.0431.  Companies with a low float frequently have a large portion of their equity held by controlling insiders such as directors and employees, which leaves only a tiny percentage of shares available for the public. That limited supply can cause significant price swings if demand changes quickly. Oragenics, Inc. (NYSE American: OGEN) is also considered a nano-cap. In general, nano-cap companies have market capitalizations of less than $50M. Because nano-caps are significantly smaller than mid cap or large cap companies, they have a higher potential for growth.  As of 8/7/2024, Oragenics, Inc. (NYSE American: OGEN) has a market cap of less than $6M (approx.) according to FinViz. Barchart is currently reporting the following moving averages for Oragenics, Inc. (NYSE American: OGEN): 5-Day: $.9545 20-Day: $1.0431 50-Day: $1.3140 100-Day: $1.3753 200-Day: $2.6266 Not to mention that as of this writing, on 8/7/2024, Oragenics, Inc. (NYSE American: OGEN) is triggering a staggering 16 Bullish Signals on TradingView’s technical analysis tool for the 5-minute time frame. Keep reading to see why you need to add Oragenics, Inc. (NYSE American: OGEN) to the top of your watchlist right now. Oragenics, Inc. (NYSE American: OGEN) is making remarkable progress in the biotechnology sector with its cutting-edge approach to pharmaceutical medication delivery.  As a development-stage company, Oragenics focuses on nasal delivery systems for treating neurological conditions and infectious diseases.  This pioneering company is rapidly gaining attention with its promising candidates aimed at addressing mild traumatic brain injury (mTBI), commonly known as concussions, and Niemann-Pick Disease Type C (NPC). Breakthrough in Concussion Treatment One of the most exciting recent developments for Oragenics is their enhanced formulation for ONP-002, a novel neurosteroid designed to treat concussions. The company has successfully advanced ONP-002, making significant improvements in its intranasal formulation. This novel chemical entity (NCE) is designed to target the brain through the nasal cavity, offering a rapid and direct route to the central nervous system. The newly improved formulation of ONP-002 aims to deliver therapeutic levels of the dr-ug more effectively. Oragenics has increased the final dose levels and enhanced the adhesion within the nasal cavity, thereby extending absorption times. This advancement is expected to significantly boost the bioavailability of ONP-002, ensuring that more of the dr-ug reaches the brain where it is needed most. Dr. James Kelly, Chief Medical Officer at Oragenics, expressed his enthusiasm about these advancements: “We are thrilled about the recent modifications to our novel intranasal formulation. Anything that can be done to drive more chemical protection to the brain during the acute pathological cascade will help reduce negative outcomes in the concussed population.” Addressing a Critical Medical Need Concussions are a serious and widespread medical issue, with an estimated 69 Mln cases reported annually worldwide. The causes are varied, ranging from falls and motor vehicle accidents to military incidents and contact sports. The link between concussions and long-term neurological disorders such as Alzheimer’s Disease, Parkinson’s Disease, and Chronic Traumatic Encephalopathy (CTE) underscores the urgent need for effective treatments. Oragenics, Inc. (NYSE American: OGEN)’s ONP-002 holds the potential to reduce the duration and severity of initial concussion symptoms and prevent the development of long-lasting, debilitating symptoms. This is a significant breakthrough, considering that post-concussion symptoms can lead to long-term disability in up to 20% of patients. Future Prospects and Impact The Phase II study planned by Oragenics will be critical in assessing the safety and feasibility of ONP-002 while analyzing its effectiveness through patient blood biomarker profiles and functional outcomes. This study could pave the way for a revolutionary treatment option for concussed patients, addressing a substantial unmet medical need. Oragenics, Inc. (NYSE American: OGEN) is not just focusing on concussions. Their platform includes proprietary intranasal formulations and devices aimed at delivering medications for various neurological and infectious diseases. This holistic approach positions Oragenics as a leader in the development of innovative treatments that could transform the medical landscape. New Automated Intranasal Device In a recent announcement, Oragenics unveiled a prototype of their automated intranasal device designed for use in concussed patients who are initially confused, dazed, or unconscious in the acute phase of injury. This breath-propelled device aims to administer ONP-002 effectively even when patients cannot follow instructions, ensuring timely treatment during critical moments. This development addresses a vital need, as loss of consciousness and acute memory impairment can significantly impact clinical outcomes. Michael Redmond, President at Oragenics, highlighted the significance of this innovation: “We are excited about this new automated technology as it allows us to treat the full range of concussive injuries. Both devices offer advantages and can deliver our nanoparticle powder. Given the early mental alterations many concussed patients experience, we aim to provide them the best dr-ug delivery route to improve their clinical outcomes.” Oragenics, Inc. (NYSE American: OGEN) is at the forefront of biotechnological innovation, with its cutting-edge intranasal delivery systems and promising candidates. The recent advancements in their ONP-002 formulation for treating concussions highlight their commitment to addressing critical medical needs and improving patient outcomes. As they move forward with their Phase II study and further developments, Oragenics is poised to make a significant impact in the field of neurology and beyond. Industry stakeholders should keep a close eye on Oragenics, Inc. (NYSE American: OGEN), as their groundbreaking work continues to unfold, potentially revolutionizing the treatment of concussions and other neurological disorders.  7 reasons why Oragenics, Inc. (NYSE American: OGEN) needs to be at the top of your watchlist right now. 1. Technical Indicators: As of earlier today, August 7, 2024, Oragenics, Inc. (NYSE American: OGEN) is triggering 16 bullish signals on TradingView’s technical analysis tool for the 5-minute time frame, highlighting strong positive sentiment. 2. Low Float and a Higher Potential for Growth: Oragenics, Inc. (NYSE American: OGEN) has less than 5.1M shares in its float and a market cap of less than $6M, which often leads to significant price swings and higher growth potential compared to larger companies. 3. Innovative Biotechnology: Oragenics, Inc. (NYSE American: OGEN) is leading the way in pharmaceutical medication delivery through nasal systems, focusing on critical areas such as neurological conditions and infectious diseases. 4. Breakthrough Formulation: The enhanced formulation of ONP-002, a novel neurosteroid for concussion treatment, demonstrates Oragenics, Inc. (NYSE American: OGEN)’s ability to innovate and improve efficacy. 5. Addressing Major Medical Needs: With 69 Mln concussions reported annually worldwide, Oragenics, Inc. (NYSE American: OGEN)’s ONP-002 has the potential to significantly impact patient outcomes and reduce long-term disabilities. 6. Promising Phase II Study: The upcoming Phase II study will evaluate the safety and effectiveness of ONP-002, paving the way for potential breakthroughs in concussion treatment. 7. Automated Intranasal Device: The development of an automated intranasal device for concussed patients ensures effective delivery even when patients are unable to follow instructions, addressing critical early-phase treatment needs. Oragenics, Inc. (NYSE American: OGEN) stands at the forefront of biotechnological innovation, revolutionizing pharmaceutical medication delivery with its cutting-edge intranasal systems and promising candidates. The company's recent advancements in the ONP-002 formulation for treating concussions underscore their dedication to addressing critical medical needs and improving patient outcomes. As Oragenics advances with its Phase II study and further developments, it is poised to make a significant impact in the field of neurology and beyond. With less than 5.1M shares available in the float, Oragenics, Inc. (NYSE American: OGEN) offers the potential for significant price swings if demand changes quickly. As of August 7, 2024, the company is triggering 16 bullish signals on TradingView’s technical analysis tool for the 5-minute time frame, indicating strong positive sentiment. Oragenics, Inc. (NYSE American: OGEN) leads the way in innovative biotechnology, focusing on critical areas such as neurological conditions and infectious diseases.  The breakthrough formulation of ONP-002, a novel neurosteroid for concussion treatment, demonstrates the company's ability to innovate and improve efficacy.  Addressing major medical needs, such as the 69 Mln concussions reported annually worldwide, ONP-002 has the potential to significantly impact patient outcomes and reduce long-term disabilities. The upcoming Phase II study will be crucial in evaluating the safety and effectiveness of ONP-002, paving the way for potential breakthroughs in concussion treatment.  Beyond concussions, Oragenics is developing proprietary intranasal formulations and devices for a range of neurological and infectious diseases, showcasing a broad and impactful therapeutic approach. The development of an automated intranasal device for concussed patients ensures effective delivery even when patients are unable to follow instructions, addressing critical early-phase treatment needs. Led by industry experts like Dr. James Kelly and Michael Redmond, Oragenics is committed to advancing medical science and improving clinical outcomes, positioning the company as a pioneer in the biotech industry. Given these reasons, it’s clear why Oragenics, Inc. (NYSE American: OGEN) needs your attention.  Immediately add Oragenics, Inc. (NYSE American: OGEN) to the top of your watchlist. Do not miss out on Oragenics, Inc. (NYSE American: OGEN) this morning. But keep in mind, there’s less than 5.1M shares available to the public. I’ll check back in with you again shortly. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux (MarketCrux . com) is owned by Headline Media LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. MarketCrux full disclosure is to be read and fully understood before using MarketCrux website, or joining MarketCrux's email or text list. By viewing MarketCrux website and/or reading MarketCrux email or text newsletter you are agreeing to MarketCrux full disclosure which can be read at marketcrux.com/disclaimer  Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 08/07/2024 and ending on 08/08/2024 to publicly disseminate information about (OGEN:US) via digital communications. Headline Media LLC has been paid five thousand USD. We own zero shares of (OGEN:US). Please see important disclosure information here: https://marketcrux.com/ogen-disclosure-7637/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice